London: German drug vial manufacturer Gerresheimer announced on monday Expansion The company has decided to close its U.S. production site as it sees growing demand for weight loss drugs, including the GLP-1 class.

The company is investing around 166 million euros ($180.24 million) in the construction of two buildings, which will create 400 new jobs in Peachtree.

The site makes autoinjectors that can be used in diabetes and obesity therapies, such as Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound, in addition to other medical devices.

(Reporting by Marlene Casebier and Isabelle Demetz; Editing by Andrey Sychev)